Armenia vs France: Pneumococcal conjugate second or third-dose vaccines (PCVc)
Armenia
96.0%
in 2025
France
96.0%
in 2025
Armenia rank
26th
France rank
26th
Pneumococcal conjugate second or third-dose vaccines (PCVc) over time
- Armenia
- France
How they compare
Armenia currently reports 96.0% against 96.0% in France, a difference of 0.0%.
The two have swapped places 2 times across 18 shared years of data; in 2008 it was France ahead.
Armenia ranks 26th and France ranks 26th of 192 countries.
France has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Armenia | France | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | β |
| 2010s | 41.6% | 90.5% | 48.9% | France |
| 2020s | 93.7% | 95.7% | 2.0% | France |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pneumococcal conjugate second or third-dose vaccines (pcvc), Armenia or France?
- Armenia, at 96.0% against 96.0% in France as of 2025.
- What is the difference in pneumococcal conjugate second or third-dose vaccines (pcvc) between Armenia and France?
- 0.0%, with Armenia ahead.
- How many years of comparable data are there for Armenia and France?
- 18 years are reported by both, from 2008 to 2025.
- How do Armenia and France rank globally for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Armenia ranks 26th and France ranks 26th of 192 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid refreshes it automatically from the source and publishes the full history for both places.